Having trouble accessing articles? Reset your cache.

Campath alemtuzumab: Phase II data

Data from a Phase II trial in 34 evaluable patients showed that alemtuzumab plus fludarabine

Read the full 153 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE